Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Asenapine · Saphris, Secuado

Small molecule · Antagonist of dopamine D2 receptor (DRD2) and 5-hydroxytryptamine 2A receptor (HTR2A) · developed by Abbvie

Approved FDA, Aug 2009
1 Registered trials

What is Asenapine?

Asenapine is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors. It is used in the treatment of schizophrenia and bipolar I disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Saphris, Secuado
Drug type
Small molecule
Targets
dopamine D2 receptor (DRD2), 5-hydroxytryptamine 2A receptor (HTR2A)
Mechanism
Antagonist of dopamine D2 receptor (DRD2) and 5-hydroxytryptamine 2A receptor (HTR2A)
Therapy area
Psychiatry
Developer
Abbvie
In trials of
AMRX
FDA status
Approved as Saphris, Secuado (August 13, 2009), NDA022117 · FDA label
UNII
JKZ19V908O

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 31, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02072954 Phase 2/3 Schizophrenia Completed AMRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

Other drugs acting on DRD2 / HTR2A

Aripiprazole Lauroxil FDA approved Iloperidone FDA approved Milsaperidone FDA approved Pimavanserin FDA approved ONC206 Phase 2 Psilocybin Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.